[go: up one dir, main page]

SI2167128T1 - Z genetskim inĺ˝enirstvom pridobljena hibridna protitelesa proti alfa v- integrinu - Google Patents

Z genetskim inĺ˝enirstvom pridobljena hibridna protitelesa proti alfa v- integrinu

Info

Publication number
SI2167128T1
SI2167128T1 SI200830845T SI200830845T SI2167128T1 SI 2167128 T1 SI2167128 T1 SI 2167128T1 SI 200830845 T SI200830845 T SI 200830845T SI 200830845 T SI200830845 T SI 200830845T SI 2167128 T1 SI2167128 T1 SI 2167128T1
Authority
SI
Slovenia
Prior art keywords
alpha
hybrid antibodies
engineered anti
integrin hybrid
integrin
Prior art date
Application number
SI200830845T
Other languages
English (en)
Inventor
Simon Goodman
Diane Hahn
Francesc Mitjans
Jaume Adan
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI2167128T1 publication Critical patent/SI2167128T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200830845T 2007-07-17 2008-07-17 Z genetskim inĺ˝enirstvom pridobljena hibridna protitelesa proti alfa v- integrinu SI2167128T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies
EP08784834A EP2167128B1 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (1)

Publication Number Publication Date
SI2167128T1 true SI2167128T1 (sl) 2013-01-31

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830845T SI2167128T1 (sl) 2007-07-17 2008-07-17 Z genetskim inĺ˝enirstvom pridobljena hibridna protitelesa proti alfa v- integrinu

Country Status (19)

Country Link
US (1) US8562986B2 (sl)
EP (2) EP2526967A1 (sl)
JP (1) JP5341889B2 (sl)
KR (1) KR101559596B1 (sl)
CN (1) CN101687039B (sl)
AU (1) AU2008277907B2 (sl)
BR (1) BRPI0815567B8 (sl)
CA (1) CA2693863C (sl)
CY (1) CY1113493T1 (sl)
DK (1) DK2167128T3 (sl)
EA (1) EA019485B1 (sl)
ES (1) ES2395799T3 (sl)
HR (1) HRP20120949T1 (sl)
IL (1) IL203269A (sl)
PL (1) PL2167128T3 (sl)
PT (1) PT2167128E (sl)
SI (1) SI2167128T1 (sl)
WO (1) WO2009010290A2 (sl)
ZA (1) ZA201001124B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004129A1 (en) 2008-12-23 2012-01-05 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
SG178348A1 (en) * 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
WO2015035215A1 (en) * 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
ES2856348T3 (es) 2014-09-17 2021-09-27 Merck Patent Gmbh Un método para el tratamiento de cánceres sólidos y/o metástasis de los mismos, medicamentos relacionados, y un método para la predicción de la evolución clínica del tratamiento de cánceres sólidos y/o metástasis de los mismos
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
TW201720843A (zh) * 2015-11-23 2017-06-16 馬克專利公司 用於治療纖維化及／或纖維化病症之抗－αＶ整合素抗體
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
WO2018046610A1 (en) 2016-09-08 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
JP7150723B2 (ja) 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のインテグリン阻害薬による治療
JP7123063B2 (ja) 2017-02-02 2022-08-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ドメインの好ましい対形成
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
EP3692060A1 (en) 2017-10-03 2020-08-12 Merck Patent GmbH Cysteine engineered antigen-binding molecules
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US12171829B2 (en) 2018-10-19 2024-12-24 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
ATE352559T1 (de) * 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
MXPA05005558A (es) 2002-11-26 2005-07-26 Protein Design Labs Inc Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis.
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
ES2365046T3 (es) * 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
WO2007084620A2 (en) 2006-01-19 2007-07-26 Bassler G Scott Rapid food chiller

Also Published As

Publication number Publication date
JP2010533480A (ja) 2010-10-28
KR20100057010A (ko) 2010-05-28
AU2008277907B2 (en) 2013-08-22
CA2693863C (en) 2017-10-03
EA019485B1 (ru) 2014-04-30
EP2167128A2 (en) 2010-03-31
BRPI0815567B1 (pt) 2019-06-04
BRPI0815567B8 (pt) 2021-05-25
IL203269A (en) 2014-11-30
KR101559596B1 (ko) 2015-10-12
ES2395799T3 (es) 2013-02-15
US8562986B2 (en) 2013-10-22
PT2167128E (pt) 2013-01-24
ZA201001124B (en) 2010-11-24
CY1113493T1 (el) 2016-06-22
EP2526967A1 (en) 2012-11-28
EP2167128B1 (en) 2012-10-24
PL2167128T3 (pl) 2013-03-29
AU2008277907A1 (en) 2009-01-22
CN101687039A (zh) 2010-03-31
WO2009010290A3 (en) 2009-04-09
DK2167128T3 (da) 2012-12-03
WO2009010290A2 (en) 2009-01-22
HK1143523A1 (en) 2011-01-07
BRPI0815567A2 (pt) 2015-02-18
HRP20120949T1 (en) 2012-12-31
JP5341889B2 (ja) 2013-11-13
EA201070150A1 (ru) 2010-08-30
US20100254977A1 (en) 2010-10-07
CA2693863A1 (en) 2009-01-22
CN101687039B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
ZA201001124B (en) Engineered anti-alpha v-integrin hybrid antibodies
HRP20182174T1 (hr) Anti-il-23p19 antitijela proizvedena genetičkim inženjeringom
IL200581A0 (en) Engineered anti-il-23r antibodies
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
GB0821100D0 (en) Antibodies
IL198424A0 (en) Hybrid immunoglobulins with moving parts
PL2146745T3 (pl) Pięcioswoiste przeciwciało
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en) Antibodies
IL201552A0 (en) Antibodies against il-25
IL207581A0 (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
IL205073A0 (en) Anti-bst2 antibody
GB0817891D0 (en) Antibodies against il-25
ZA201007976B (en) Anti-pirb antibodies
EP2217626A4 (en) EPITOP FOR NEUTRALIZING ANTIBODIES
GB0818356D0 (en) Antibodies
HK1126789A (en) Engineered anti-il-23r antibodies
HK1144582A (en) Engineered anti-tslpr antibodies
GB0724185D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies